Lakefront Biotherapeutics NV annual debt-to-ebitda ratio
2019
2022
2023
2024
2025
Lakefront Biotherapeutics NV Debt-to-EBITDA Ratio Growth & History (LKFT)
Lakefront Biotherapeutics NV's debt-to-ebitda ratio was 0.02 for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.02 | −0.25 | −92.88% |
| 2024 | 2024-12-31 | 0.27 | 0.08 | +43.90% |
| 2023 | 2023-12-31 | 0.19 | −5.47 | −96.68% |
| 2022 | 2022-12-31 | 5.66 | — | — |
| 2019 | 2019-12-31 | 0.07 | — | — |
Lakefront Biotherapeutics NV quarterly debt-to-ebitda ratio
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | — | — |
| Q1 2026 | 2026-03-31 | 0.02 | — | — |
| Q4 2025 | 2025-12-31 | 0.02 | — | — |
Lakefront Biotherapeutics NV debt-to-ebitda ratio trends
Between the periods ended 2019-12-31 and 2025-12-31, Lakefront Biotherapeutics NV's debt-to-ebitda ratio decreased from 0.07 to 0.02, a change of −0.05. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗